Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Fate Therapeutics, Inc. (FATE) had Return on Equity of -19.66% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$2.08M |
|
$-30.16M |
|
-- |
|
$2.08M |
|
$33.22M |
|
$-31.13M |
|
$0.97M |
|
$-30.16M |
|
$-30.16M |
|
$-30.16M |
|
$-30.16M |
|
$-30.16M |
|
$-30.16M |
|
$-31.13M |
|
$-29.12M |
|
120.40M |
|
120.40M |
|
$-0.25 |
|
$-0.25 |
|
| Balance Sheet Financials | |
$157.95M |
|
$51.55M |
|
$102.15M |
|
$260.10M |
|
$32.59M |
|
-- |
|
$74.07M |
|
$106.67M |
|
$153.43M |
|
$153.44M |
|
$153.44M |
|
116.69M |
|
| Cash Flow Statement Financials | |
$-54.26M |
|
$38.14M |
|
$1.74M |
|
$56.85M |
|
$42.48M |
|
$-14.38M |
|
$7.45M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.85 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1495.39% |
|
-1495.39% |
|
-- |
|
-1448.56% |
|
-1448.56% |
|
$-54.58M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
2.96 |
|
30.39 |
|
|
Return on Equity |
-19.66% |
-19.66% |
|
-11.60% |
|
-19.66% |
|
$1.31 |
|
$-0.45 |
|
$-0.45 |
|